The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial. / Melau, Marianne; Jeppesen, Pia; Thorup, Anne; Bertelsen, Mette; Petersen, Lone; Gluud, Christian Nyfeldt; Krarup, Gertrud; Nordentoft, Merete.

In: Trials, Vol. 12, 01.01.2011, p. 72.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Melau, M, Jeppesen, P, Thorup, A, Bertelsen, M, Petersen, L, Gluud, CN, Krarup, G & Nordentoft, M 2011, 'The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial', Trials, vol. 12, pp. 72. https://doi.org/10.1186/1745-6215-12-72, https://doi.org/10.1186/1745-6215-12-72

APA

Melau, M., Jeppesen, P., Thorup, A., Bertelsen, M., Petersen, L., Gluud, C. N., Krarup, G., & Nordentoft, M. (2011). The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial. Trials, 12, 72. https://doi.org/10.1186/1745-6215-12-72, https://doi.org/10.1186/1745-6215-12-72

Vancouver

Melau M, Jeppesen P, Thorup A, Bertelsen M, Petersen L, Gluud CN et al. The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial. Trials. 2011 Jan 1;12:72. https://doi.org/10.1186/1745-6215-12-72, https://doi.org/10.1186/1745-6215-12-72

Author

Melau, Marianne ; Jeppesen, Pia ; Thorup, Anne ; Bertelsen, Mette ; Petersen, Lone ; Gluud, Christian Nyfeldt ; Krarup, Gertrud ; Nordentoft, Merete. / The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial. In: Trials. 2011 ; Vol. 12. pp. 72.

Bibtex

@article{558943283d6743e28901c6d5d890e3d5,
title = "The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial",
abstract = "Background The Danish OPUS I trial randomized 547 patients with first-episode psychosis to a two-year early-specialised assertive treatment programme (OPUS) versus standard treatment. The two years OPUS treatment had significant positive effects on psychotic and negative symptoms, secondary substance abuse, treatment adherence, lower dosage of antipsychotic medication, and a higher treatment satisfaction. However, three years after end of the OPUS treatment, the positive clinical effects were not sustained, except that OPUS-treated patients were significantly less likely to be institutionalised compared with standard-treated patients. The major objective of the OPUS II trial is to evaluate the effects of five years of OPUS treatment versus two years of OPUS treatment. Methods The OPUS II trial is designed as a randomized, open label, parallel group trial with blinded outcome assessment. Based on our sample size estimation, 400 patients treated in OPUS for two years will be randomized to further three years of OPUS treatment versus standard treatment. The specialized assertive OPUS treatment consists of three core elements: assertive community treatment, psycho-educational family treatment, and social skills training. Discussion It has been hypothesized that there is a critical period from onset up to five years, which represents a window of opportunity where a long-term course can be influenced. Extending the specialized assertive OPUS treatment up to five years may allow the beneficial effects to continue beyond the high-risk period, through consolidation of improved social and functional outcome. Trial registration Clinical Trial.gov NCT00914238 ",
author = "Marianne Melau and Pia Jeppesen and Anne Thorup and Mette Bertelsen and Lone Petersen and Gluud, {Christian Nyfeldt} and Gertrud Krarup and Merete Nordentoft",
year = "2011",
month = jan,
day = "1",
doi = "10.1186/1745-6215-12-72",
language = "English",
volume = "12",
pages = "72",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial

AU - Melau, Marianne

AU - Jeppesen, Pia

AU - Thorup, Anne

AU - Bertelsen, Mette

AU - Petersen, Lone

AU - Gluud, Christian Nyfeldt

AU - Krarup, Gertrud

AU - Nordentoft, Merete

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background The Danish OPUS I trial randomized 547 patients with first-episode psychosis to a two-year early-specialised assertive treatment programme (OPUS) versus standard treatment. The two years OPUS treatment had significant positive effects on psychotic and negative symptoms, secondary substance abuse, treatment adherence, lower dosage of antipsychotic medication, and a higher treatment satisfaction. However, three years after end of the OPUS treatment, the positive clinical effects were not sustained, except that OPUS-treated patients were significantly less likely to be institutionalised compared with standard-treated patients. The major objective of the OPUS II trial is to evaluate the effects of five years of OPUS treatment versus two years of OPUS treatment. Methods The OPUS II trial is designed as a randomized, open label, parallel group trial with blinded outcome assessment. Based on our sample size estimation, 400 patients treated in OPUS for two years will be randomized to further three years of OPUS treatment versus standard treatment. The specialized assertive OPUS treatment consists of three core elements: assertive community treatment, psycho-educational family treatment, and social skills training. Discussion It has been hypothesized that there is a critical period from onset up to five years, which represents a window of opportunity where a long-term course can be influenced. Extending the specialized assertive OPUS treatment up to five years may allow the beneficial effects to continue beyond the high-risk period, through consolidation of improved social and functional outcome. Trial registration Clinical Trial.gov NCT00914238

AB - Background The Danish OPUS I trial randomized 547 patients with first-episode psychosis to a two-year early-specialised assertive treatment programme (OPUS) versus standard treatment. The two years OPUS treatment had significant positive effects on psychotic and negative symptoms, secondary substance abuse, treatment adherence, lower dosage of antipsychotic medication, and a higher treatment satisfaction. However, three years after end of the OPUS treatment, the positive clinical effects were not sustained, except that OPUS-treated patients were significantly less likely to be institutionalised compared with standard-treated patients. The major objective of the OPUS II trial is to evaluate the effects of five years of OPUS treatment versus two years of OPUS treatment. Methods The OPUS II trial is designed as a randomized, open label, parallel group trial with blinded outcome assessment. Based on our sample size estimation, 400 patients treated in OPUS for two years will be randomized to further three years of OPUS treatment versus standard treatment. The specialized assertive OPUS treatment consists of three core elements: assertive community treatment, psycho-educational family treatment, and social skills training. Discussion It has been hypothesized that there is a critical period from onset up to five years, which represents a window of opportunity where a long-term course can be influenced. Extending the specialized assertive OPUS treatment up to five years may allow the beneficial effects to continue beyond the high-risk period, through consolidation of improved social and functional outcome. Trial registration Clinical Trial.gov NCT00914238

U2 - 10.1186/1745-6215-12-72

DO - 10.1186/1745-6215-12-72

M3 - Journal article

C2 - 21392377

VL - 12

SP - 72

JO - Trials

JF - Trials

SN - 1745-6215

ER -

ID: 34108339